Galera Therapeutics, Inc.
GRTXDelisted Sep 6, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001563577
Galera Therapeutics, Inc. was delisted on Sep 6, 2024; its insiders filed their last Form 4 on Aug 5, 2026; 36 institutions reported holding it in 13F filings for Q1 2024, worth $1.37M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Galera Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Galera Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Sorensen Mel | President and CEO | 0 | Aug 5, 2026 | 2 |
| Lokay Kevin G | Director | – | Aug 5, 2026 | 1 |
| Chang Nancy T | Director, 10% Owner | 0 | Aug 5, 2026 | 2 |
| Alleva Lawrence M | Director | 0Indirect | Aug 5, 2026 | 1 |
| Sussman Joel F. | Chief Accounting Officer | – | Aug 5, 2026 | 1 |
| Friedman Michael R. | Director | 0Indirect | Aug 5, 2026 | 2 |
| Opler Timothy | 10% Owner | 61,029,978 | May 29, 2026 | 1 |
| Emerald Bioventures, LLC | 10% Owner | 61,029,978 | May 29, 2026 | 1 |
| Schneid Yair | 10% Owner | 10,823,610 | May 1, 2024 | 0 |
| West Linda | Director | 60,000 | Jul 5, 2023 | 0 |
| Powell Michael | Director | – | Jun 16, 2023 | 0 |
| Cunningham Emmett | Director | – | Jun 16, 2023 | 0 |
| Bachleda Mark | Chief Commercial Officer | 11,000 | Mar 20, 2023 | 0 |
| Degnan Chris | Chief Financial Officer | 10,000 | Mar 14, 2023 | 0 |
| Beardsley Robert A | Chief Operating Officer | 108,191 | Feb 28, 2023 | 0 |
| Stacey Jennifer Evans | See Remarks | – | Feb 28, 2023 | 0 |
| Kennedy Eugene P. | Chief Medical Officer | – | Feb 28, 2023 | 0 |
| Holmlund Jon T | Chief Medical Officer | 0 | Mar 2, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 24, 2025 (view filing)4:42 PM ET | Nov 20 | 4 days | Sorensen MelPresident and CEO | SSale | −70.0K | $0.0201 | −$1.41K | −26.4%195.0K after | |
| Jan 2, 2025 (view filing)4:12 PM ET | Dec 30, 2024 | 3 days | Chang Nancy TDirector, 10% Owner | PPurchase | +7.64M | $0.0654 | +$500.0K | New position7.64M after | |
| Aug 20, 2024 (view filing)4:45 PM ET | Aug 16 | 4 days | Sorensen MelPresident and CEO | SSale | −67.0K | $0.072 | −$4.83K | −20.2%265.0K after | |
| May 1, 2024 (view filing)5:02 PM ET | Apr 17, 2014-Apr 19, 2024 | 3,667 days | Schneid Yair10% Owner | PPurchase | +2.78M | $0.2124 | +$590.4K | +34.6%10.8M after | Amended21 lots |
| Mar 20, 2023 (view filing) | Mar 16 | 4 days | Bachleda MarkChief Commercial Officer | PPurchase | +11.0K | $2.25 | +$24.8K | New position11.0K after | |
| Mar 14, 2023 (view filing) | Mar 10 | 4 days | Sorensen MelPresident and CEO | PPurchase | +100.0K | $1.68 | +$168.0K | +43.1%332.0K after | |
| Mar 14, 2023 (view filing) | Mar 13 | 1 day | Degnan ChrisChief Financial Officer | PPurchase | +10.0K | $1.96 | +$19.6K | New position10.0K after | |
| Dec 20, 2021 (view filing) | Dec 17 | 3 days | West LindaDirector | PPurchase | +20.0K | $2.74 | +$54.8K | +50.0%60.0K after | |
| Sep 3, 2021 (view filing) | Sep 1 | 2 days | Holmlund Jon TChief Medical Officer | SSale | −47.8K | $8.47 | −$404.5K | −100.0%0 after |